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303 Kwashiorkor − a clinical manifestation of cystic ﬁbrosis
A. Mehl1, C. Rolinck-Werninghaus1, D. Staab1. 1Charite´ − University Medical
Centre Berlin, Departmen of Pediatric Pneumonology and Immunology, Berlin,
Germany
Background: A 4-month-old boy presented with failure to thrive. At hospital
admission, with edema and worsening general condition, he had tachypnoea and
desaturations, pale and marmorate skin, edema and liver enlargement. Weight was
below the third centile. Laboratory tests revealed anaemia, hypoalbuminaemia,
increased liver function tests and increased cell count in cerebrospinal ﬂuid.
CMV-PCR was positive in plasma, CSF and urine. He was under treatment with
ganciclovir, ampicillin/sulbactam and daily substitution of human albumine.
Fecal elastase was <15mg/g, sweat test was normal (28mmol/l). Due to liver failure,
devastating general condition, apathy, no spontaneous body movements, dyspnea,
hepatomegaly, edema and erythematous eruptions the child was transferred to our
clinic.
Pancreatic enzyme replacement and oral supplementation of vitamin D, K, E
and zinc was initiated, antibiotics and antivirals continued. With this treat-
ment general condition improved, edema and skin lesions resolved, weight in-
creased and neurological status improved. Cystic ﬁbrosis (CF) was diagnosed
(sweat chloride 90mmol/l) after edema had resolved and conﬁrmed genetically
[dF508/CFTRdele2,3 (21 kb)].
Discussion and Conclusion: CF still may present with life-threatening anemia,
hypalbuminaemia and edema (kwashiorkor). Infections due to impaired immuno-
logical status can further complicate the clinical course. False negative sweat tests
are reported with kwashiorkor and must not lead to the exclusion of CF. To avoid
these life-threatning conditions implementation of CF newborn screening is urgently
demanded.
We will present cases of CF presenting with kwashiorkor from our clinic from
previous years.
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Objectives: The most common co-morbidity of cystic ﬁbrosis is probably diabetes.
Pharmacotherapy of cystic ﬁbrosis related diabetes (CFRD) is so far restricted
to treatment with insulin. The primary defect in CFRD is a progressive insulin
deﬁciency. In CFRD the incretin system is impaired and postprandial hyperglycemia
the major clinical problem. In type 2 diabetes incretin-based treatment improves
glucose-dependent insulin release and minimizes the risk of hypoglycemia. The
introduction of incretin-based therapy in CFRD may therefore be an alternative
or complement to insulin treatment. The aim of this study is to investigate if
oral incretin therapy with a dipeptidyl peptidase-4 (DPP-4) inhibitor is useful for
treatment of CFRD.
Methods: The DPP-4 inhibitor sitagliptin was given to 8 patients with CFRD
with previous insulin therapy. All subjects suffered from problems with the glucose
regulation. Six patients received 100mg sitagliptin once daily and one patient 50mg.
Six patients were treated only with sitagliptin and 2 patients received additional
insulin. So far the duration of the sitagliptin treatment varies from 2 to 21 months.
Results: The sitagliptin treatment was well tolerated without side effects. All
subjects reached a stable and satisfactory glycemic control.
Conclusion: Incretin-based therapy with DDP-4 inhibitors is a promising new
alternative for treatment of CFRD.
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Introduction: Clostridium difﬁcile-associated disease (CDAD) is a problem widely
seen in clinical care. C. difﬁcile colitis can cause life-threatening illness in patients
with cystic ﬁbrosis (CF) and may present late with mild or atypical symptoms. We
report the use of a novel antibiotic therapy, ﬁdaxomicin, in the treatment of CDAD
in a patient with severe CF.
Results: A 39 year old female CF patient on the lung transplantation waiting list had
multiple episodes of CDAD over a 6-year period associated with intravenous (IV)
antibiotics, oral steroids and proton pump inhibitors, including an episode of
severe pancolitis necessitating stopping IV antibiotics and PPIs. Both glutamate
dehydrogenase (GDH) and C. difﬁcile toxin were positive on numerous occasions
prior to May 2013. At this time, her CDAD was initially treated with oral
vancomycin 250mg QDS for 9 days. Her symptoms worsened and therefore a 10
day course of oral ﬁdaxomicin was commenced. Her symptoms and CRP improved
following this course. Despite numerous admissions since she has had only one
signiﬁcant episode of diarrhoea (GDH positive but C. difﬁcile toxin negative); this
did not require treatment. She experienced no adverse effects from ﬁdaxomicin
and has had no further symptoms of CDAD despite an increasing burden of IV
antibiotic therapy and continued PPI.
Conclusion: This is the ﬁrst reported case of ﬁdaxomicin use for CDAD in CF. It
can prevent recurrence of CDAD in CF patients and has lower CDAD recurrence
rates over a 28 day period compared to vancomycin (Cornely 2012). This is thought
to be due to its higher speciﬁcity to Clostridium difﬁcile (Louie 2012).
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Introduction: CF related low bone mineral density (BMD) occurs in 34% of
CF patients. Guidelines on its management advocate a combination of preventative
and treatment strategies including use of bisphosphonates. Long-term bisphospho-
nate therapy has been linked to atypical fractures with clearly deﬁned features
however this has not been reported in CF. We report a case of a CF patient with
bisphosphonate use leading to atypical femoral fracture.
Results: A 54 year old CF male on long term prednisolone for allergic bronchopul-
monary aspergillosis was on daily Calcichew D3 forte and weekly alendronic acid
for ﬁve years and changed to monthly ibandronate for the next four years due to
worsening BMD on DXA scan. This was stopped after he sustained a low-impact
fracture of the 5th metatarsal bone and replaced with daily subcutaneous Teriparatide
to aid bone healing. A year later he complained of worsening left groin pain
without any prior history of trauma. Pelvic Xray revealed an undisplaced transverse
lateral cortex subtrochanteric fracture ﬁtting the criteria for a bisphosphonate related
atypical fracture. He underwent intramedullary nailing of the femur. Vitamin D,
PTH, calcium and Procollagen Type 1 Amino Terminal Peptide (P1NP) levels were
normal. Bone biopsy showed degenerative change. Urinary NTX is awaited. He
remains on crutches ﬁve months postoperatively due to poor bone healing.
Conclusion: This is the ﬁrst reported case of bisphosphonate related atypical
femoral fracture in a CF patient and highlights the importance of recognising
unusual drug side effects in an ageing CF population with multimorbidity and
polypharmacy and consideration of a ‘drug holiday’.
